{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:38:14Z","timestamp":1761748694709,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.acvd.2016.07.001","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T21:28:31Z","timestamp":1475270911000},"page":"634-640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Place of non-vitamin K antagonist oral anticoagulants in anticoagulant\u2013antiplatelet combinations in peripheral artery disease"],"prefix":"10.1016","volume":"109","author":[{"given":"Dominique","family":"Stephan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena-Mihaela","family":"Cordeanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina","family":"Mirea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alix","family":"Faller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Lejay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Gaertner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2016.07.001_bib0260","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1074248413501392","article-title":"Novel oral anticoagulants in cardiovascular disease","volume":"19","author":"Gallego","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.acvd.2016.07.001_bib0265","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1161\/CIRCULATIONAHA.114.013267","article-title":"Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis","volume":"132","author":"Sharma","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2016.07.001_bib0270","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fcvm.2015.00030","article-title":"Anticoagulant treatment of deep vein thrombosis and pulmonary embolism: the present state of the art","volume":"2","author":"Thaler","year":"2015","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.acvd.2016.07.001_bib0275","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/heartjnl-2015-307489","article-title":"Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis","volume":"101","author":"Caldeira","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2016.07.001_bib0280","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1517\/14740338.2015.1024222","article-title":"Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation","volume":"14","author":"Zoppellaro","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.acvd.2016.07.001_bib0285","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2016.07.001_bib0290","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2016.07.001_bib0295","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"Ageno","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.acvd.2016.07.001_bib0300","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2016.07.001_bib0305","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7861\/clinmedicine.16-2-152","article-title":"Antiplatelet therapy - a summary for the general physicians","volume":"16","author":"Thachil","year":"2016","journal-title":"Clin Med"},{"key":"10.1016\/j.acvd.2016.07.001_bib0310","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1016\/S0021-9258(17)33098-3","article-title":"Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme","volume":"251","author":"Hemler","year":"1976","journal-title":"J Biol Chem"},{"key":"10.1016\/j.acvd.2016.07.001_bib0315","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/17425255.2016.1176141","article-title":"The pharmacodynamics of antiplatelet compounds in thrombosis treatment","volume":"12","author":"Jayakumar","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.acvd.2016.07.001_bib0320","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40265-013-0061-z","article-title":"Optimizing the use of aspirin for cardiovascular prevention","volume":"73","author":"Casado-Arroyo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.acvd.2016.07.001_bib0325","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Caprie Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2016.07.001_bib0330","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/978-3-642-29423-5_22","article-title":"Antiplatelet therapy in peripheral artery disease","author":"Violi","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.acvd.2016.07.001_bib0335","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/14740338.2012.720972","article-title":"Safety profile and bleeding risk of ticagrelor compared with clopidogrel","volume":"11","author":"May","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.acvd.2016.07.001_bib0340","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.acvd.2016.07.001_bib0345","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","volume":"32","author":"Tendera","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2016.07.001_bib0350","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Anand","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2016.07.001_bib0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2016.07.001_bib0360","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.coph.2012.12.005","article-title":"Novel anticoagulants in the therapy of peripheral arterial and coronary artery disease","volume":"13","author":"Jacomella","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.acvd.2016.07.001_bib0365","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM200105243442108","article-title":"Medical treatment of peripheral arterial disease and claudication","volume":"344","author":"Hiatt","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2016.07.001_bib0370","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2016.07.001_bib0375","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2016.07.001_bib0380","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7326\/ACPJC-2007-147-3-060","article-title":"Addition of oral anticoagulation to antiplatelet therapy did not reduce CVD events in peripheral arterial disease","volume":"147","author":"Silver","year":"2007","journal-title":"ACP J Club"},{"key":"10.1016\/j.acvd.2016.07.001_bib0385","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2016.07.001_bib0390","unstructured":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS). ClinicalTrials.gov Identifier: NCT01776424. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01776424."},{"key":"10.1016\/j.acvd.2016.07.001_bib0395","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/000331979004100402","article-title":"Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA","volume":"41","author":"Heiss","year":"1990","journal-title":"Angiology"},{"key":"10.1016\/j.acvd.2016.07.001_bib0400","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0950-821X(05)80126-4","article-title":"Platelet inhibition with ASA\/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial","volume":"8","year":"1994","journal-title":"Eur J Vasc Surg"},{"key":"10.1016\/j.acvd.2016.07.001_bib0405","first-page":"CD710020","article-title":"Antiplatelet and anticoagulant drugs for prevention of restenosis\/reocclusion following peripheral endovascular treatment","author":"Robertson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.acvd.2016.07.001_bib0410","first-page":"S7","article-title":"Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?","volume":"74","author":"Milani","year":"2009","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.acvd.2016.07.001_bib0415","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1016\/j.acvd.2016.07.001_bib0420","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2016.07.001_bib0425","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0741-5214(98)70130-2","article-title":"Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure","volume":"28","author":"Sarac","year":"1998","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.acvd.2016.07.001_bib0430","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1148\/radiology.193.2.7972781","article-title":"Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty","volume":"193","author":"Do","year":"1994","journal-title":"Radiology"},{"key":"10.1016\/j.acvd.2016.07.001_bib0435","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/01.CIR.83.1.141","article-title":"Nd:YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions. Long-term results","volume":"83","author":"Pilger","year":"1991","journal-title":"Circulation"},{"issue":"Suppl. 20","key":"10.1016\/j.acvd.2016.07.001_bib0440","first-page":"355","article-title":"Zur Rezidivprophylaxe nach perkutaner transluminaler Angioplastie (PTA): Antikoagulation versus Ticlopidin","volume":"16","author":"Schneider","year":"1987","journal-title":"Vasa"},{"key":"10.1016\/j.acvd.2016.07.001_bib0445","first-page":"CD710020","article-title":"Antiplatelet and anticoagulant drugs for prevention of restenosis\/reocclusion following peripheral endovascular treatment","author":"Dorffler-Melly","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acvd.2016.07.001_bib0450","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jvs.2006.07.044","article-title":"Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial","volume":"44","author":"Koppensteiner","year":"2006","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.acvd.2016.07.001_bib0455","unstructured":"Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with symptomatic peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities (VOYAGER PAD). ClinicalTrials.gov Identifier: NCT02504216. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02504216."},{"key":"10.1016\/j.acvd.2016.07.001_bib0460","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1526602815574687","article-title":"A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention","volume":"22","author":"Tangelder","year":"2015","journal-title":"J Endovasc Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.acvd.2016.07.001_bib0465","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S1078-5884(11)60011-7","article-title":"Chapter III: management of cardiovascular risk factors and medical therapy","volume":"42","author":"Diehm","year":"2011","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.acvd.2016.07.001_bib0470","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","article-title":"Recommended standards for reports dealing with lower extremity ischemia: revised version","volume":"26","author":"Rutherford","year":"1997","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.acvd.2016.07.001_bib0475","doi-asserted-by":"crossref","first-page":"e669S","DOI":"10.1378\/chest.11-2307","article-title":"Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Alonso-Coello","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2016.07.001_bib0480","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.acvd.2016.07.001_bib0485","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2016.07.001_bib0490","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2016.07.001_bib0495","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2016.07.001_bib0500","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2016.07.001_bib0505","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/eurheartj\/eht492","article-title":"Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF","volume":"35","author":"Jones","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2016.07.001_bib0510","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2015.06.027","article-title":"Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 Trial","volume":"66","author":"Hess","year":"2015","journal-title":"J Am Coll Cardiol"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213616301395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213616301395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:43:27Z","timestamp":1761745407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213616301395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1875213616301395"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2016.07.001","relation":{},"ISSN":["1875-2136"],"issn-type":[{"type":"print","value":"1875-2136"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Place of non-vitamin K antagonist oral anticoagulants in anticoagulant\u2013antiplatelet combinations in peripheral artery disease","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2016.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}